Inicio・Lista de Acciones・Johnson and Johnson

Johnson and Johnson

Cerrado

SectorSanidad

254.99 0.25

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

250.85

Máximo

257.39

Métricas clave
By Trading Economics
Ingresos	299M 5.5B
Ventas	1.2B 25B
P/B Media del Sector	30.889 64.641
BPA	2.9
Rentabilidad por dividendo	1.99
Margen de beneficios	21.865
Empleados	138,200
EBITDA	-1.1B 7.2B

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+10.45% upside

Dividendos
By Acuity
Rentabilidad por dividendo Media del Sector	1.99% 2.31%
Próximas Ganancias	13 oct 2026
Fecha Próximo Dividendo	8 sept 2026
Próxima Fecha de Ex Dividendo	25 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	22B 641B
Apertura anterior	254.74
Cierre anterior	254.99

Noticias sobre sentimiento de mercado

By Acuity

28%

72%

87 / 340 Clasificación en Healthcare

Johnson and Johnson Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 ago 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-market trading, supported by stronger-than-expected manufacturing PMI data for July that signals sector growth.

1 ago 2026, 00:01 UTC

Johnson & Johnson shares gained in after-market trading, reflecting a cumulative return of 0.35% since Friday's close, despite no specific news driving the movement.

31 jul 2026, 23:01 UTC

Johnson & Johnson shares are higher in after-market trading, showing notable strength amid mixed performance in U.S. markets with no specific news identified.

30 jul 2026, 18:22 UTC

News

Event

Johnson & Johnson shares are lower amid concerns over a $1 billion acquisition of Firefly Bio and a partnership with Sail Biomedicines, impacting future earnings.

29 jul 2026, 21:41 UTC

News

Johnson & Johnson lowered its fiscal year 2026 adjusted EPS guidance to $10.86 to $11.01, contributing to a decline in after-market trading.

28 jul 2026, 23:31 UTC

Johnson & Johnson shares are higher in after-market trading, remaining above their 20-day moving average after six consecutive daily gains.

27 jul 2026, 23:31 UTC

News

Social Media

Johnson & Johnson shares are higher in after-market trading following a proposed $5.5 billion settlement for ovarian talc litigation involving about 76,000 claims.

24 jul 2026, 23:26 UTC

Johnson & Johnson shares declined in after-market trading, continuing a downward trend since Friday's close, despite the broader market's stability amid bond market concerns.

23 jul 2026, 10:06 UTC

Event

Johnson & Johnson's OTTAVA™ Robotic Surgical System received FDA authorization. Shares are lower in pre-market trading amid broader market declines.

22 jul 2026, 23:36 UTC

Event

Johnson & Johnson shares are higher in after-market trading following FDA authorization of the OTTAVA™ Robotic Surgical System, the first table-integrated soft tissue robotic system.

21 jul 2026, 23:11 UTC

Shares of Johnson & Johnson are higher in after-market trading, with no specific news identified. The stock remains below its 20-day moving average.

20 jul 2026, 19:26 UTC

Social Media

News

Johnson & Johnson shares are lower today, continuing a decline since Friday. The company targets $101 billion in revenue amid bearish technical trends.

Comparación entre iguales

Cambio de precio

Johnson and Johnson previsión

Precio Objetivo

By TipRanks

10.45% repunte

Estimación a 12 Meses

Media 281 USD 10.45%

Máximo 305 USD

Mínimo 255 USD

De acuerdo con 18 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Johnson and Johnson Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

18 ratings

Comprar

Mantener

Vender

De acuerdo con 18 analistas que ofrecen calificaciones bursátiles a para Johnson and Johnson Dist en los últimos 3 meses.

Sentimiento

By Acuity

87 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.